Vanda Pharmaceuticals has reported positive Phase III results for NEREUS (tradipitant), an NK-1 receptor antagonist, for the prevention of semaglutide-associated vomiting. The company plans to discuss the findings with the FDA ahead of a potential regulatory submission.

Topics